Patching Up Phosphagenics

Who said any publicity is good publicity? It’s not so in the case of Phosphagenics (POH). As one of the ASX’s numerous mid to low profile biotechs it is still suffering reputational deficit ever since its well regarded and high profile CEO resigned after systematic “invoice irregularities” were uncovered. The shock in Melbourne’s biotech circles echoed for months with existential undertones.

Read More